{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T11:08:35Z","timestamp":1788174515127,"version":"build-2803163510"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T00:00:00Z","timestamp":1732147200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T00:00:00Z","timestamp":1732147200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s13555-024-01289-8","type":"journal-article","created":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T15:10:17Z","timestamp":1732201817000},"page":"3261-3271","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The Atopic Dermatitis Control Tool: Adaptation and Content Validation for Children and Caregivers of Children with Atopic Dermatitis"],"prefix":"10.1007","volume":"14","author":[{"given":"Chien-Chia","family":"Chuang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Pariser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Simpson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Dine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheri","family":"Fehnel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhixiao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,21]]},"reference":[{"issue":"suppl 1","key":"1289_CR1","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1159\/000370226","volume":"66","author":"C Lifschitz","year":"2015","unstructured":"Lifschitz C. The impact of atopic dermatitis on quality of life. Ann Nutr Metab. 2015;66(suppl 1):34\u201340.","journal-title":"Ann Nutr Metab"},{"issue":"12","key":"1289_CR2","first-page":"133","volume":"6","author":"CH Na","year":"2019","unstructured":"Na CH, Chung J, Simpson EL. Quality of life and disease impact of atopic dermatitis and psoriasis on children and their families. Children (Basel). 2019;6(12):133.","journal-title":"Children (Basel)."},{"issue":"6","key":"1289_CR3","doi-asserted-by":"publisher","first-page":"711","DOI":"10.2340\/00015555-2633","volume":"97","author":"J Marciniak","year":"2017","unstructured":"Marciniak J, Reich A, Szepietowski JC. Quality of life of parents of children with atopic dermatitis. Acta Derm Venereol. 2017;97(6):711\u20134.","journal-title":"Acta Derm Venereol"},{"key":"1289_CR4","doi-asserted-by":"crossref","unstructured":"Eichenfield LF, Tom WL, Chamlin SL, Feldman SR, Hanifin JM, Simpson EL, et al. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol. 2014;70(2):338\u201351.","DOI":"10.1016\/j.jaad.2013.10.010"},{"key":"1289_CR5","doi-asserted-by":"crossref","unstructured":"Lansang P, Lara-Corrales I, Bergman JN, Hong CH, Joseph M, Kim VHD, et al. Approach to the Assessment and Management of Pediatric Patients With Atopic Dermatitis: A Consensus Document. Section IV: Consensus Statements on the Assessment and Management of Pediatric Atopic Dermatitis. J Cutan Med Surg. 2019;23(suppl 5):32s-39s.","DOI":"10.1177\/1203475419882654"},{"issue":"9","key":"1289_CR6","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1111\/j.1398-9995.2012.02874.x","volume":"67","author":"J Schmitt","year":"2012","unstructured":"Schmitt J, Spuls P, Boers M, Thomas K, Chalmers J, Roekevisch E, et al. Towards global consensus on outcome measures for atopic eczema research: results of the HOME II meeting. Allergy. 2012;67(9):1111\u20137.","journal-title":"Allergy"},{"issue":"1","key":"1289_CR7","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12895-019-0095-3","volume":"19","author":"E Simpson","year":"2019","unstructured":"Simpson E, Eckert L, Gadkari A, Mallya UG, Yang M, Nelson L, et al. Validation of the Atopic Dermatitis Control Tool (ADCT\u00a9) using a longitudinal survey of biologic-treated patients with atopic dermatitis. BMC Dermatol. 2019;19(1):15.","journal-title":"BMC Dermatol"},{"issue":"3","key":"1289_CR8","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1080\/03007995.2019.1699516","volume":"36","author":"DM Pariser","year":"2020","unstructured":"Pariser DM, Simpson EL, Gadkari A, Bieber T, Margolis DJ, Brown M, et al. Evaluating patient-perceived control of atopic dermatitis: design, validation, and scoring of the atopic dermatitis control tool (ADCT). Curr Med Res Opin. 2020;36(3):367\u201376.","journal-title":"Curr Med Res Opin"},{"issue":"12","key":"1289_CR9","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1001\/jamadermatol.2022.4211","volume":"158","author":"YA Leshem","year":"2022","unstructured":"Leshem YA, Chalmers JR, Apfelbacher C, Katoh N, Gerbens LAA, Schmitt J, et al. Measuring atopic eczema control and itch intensity in clinical practice: a consensus statement from the Harmonising Outcome Measures for Eczema in Clinical Practice (HOME-CP) Initiative. JAMA Dermatol. 2022;158(12):1429\u201335.","journal-title":"JAMA Dermatol"},{"issue":"2","key":"1289_CR10","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1001\/jamadermatol.2021.4778","volume":"158","author":"B Strober","year":"2022","unstructured":"Strober B, Mallya UG, Yang M, Ganguli S, Gadkari A, Wang J, et al. Treatment outcomes associated with dupilumab use in patients with atopic dermatitis: 1-year results from the RELIEVE-AD study. JAMA Dermatol. 2022;158(2):142\u201350.","journal-title":"JAMA Dermatol"},{"key":"1289_CR11","unstructured":"Guidance for Industry Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. US Food and Drug Administration; 2009. Accessed February 8, 2024. https:\/\/www.fda.gov\/media\/77832\/download"},{"key":"1289_CR12","unstructured":"Center for Drug Evaluation and Research. Patient-Focused Drug Development: Selecting, Developing, or Modifying Fit-for-Purpose Clinical Outcome Assessments. US Food and Drug Administration; 2022. FDA publication 2022-D-1385. Accessed February 8, 2024. https:\/\/www.regulations.gov\/document\/FDA-2022-D-1385-0001"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01289-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-024-01289-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01289-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T04:49:25Z","timestamp":1732855765000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-024-01289-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,21]]},"references-count":12,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["1289"],"URL":"https:\/\/doi.org\/10.1007\/s13555-024-01289-8","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,21]]},"assertion":[{"value":"19 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"E.S. received personal fees from AbbVie, Amgen, Arena Pharmaceuticals, Benevolent AI Bio Limited \u201cBAI\u201d, BiomX Ltd, Bluefin Biomedicine, Boehringer Ingelheim, Boston Consulting Group, Collective Acumen LLC (CA), Coronado, Dermira, Eli Lilly, Evidera, Excerpta Medica, Forte Bio RX, Incyte, Janssen, Kyowa Kirin Pharmaceutical Development, LEO Pharma, Medscape LLC, Ortho Dermatologics, Pfizer, Regeneron, Sanofi, and SPARC India; and grants (or principal investigator role) from AbbVie, Amgen, Eli Lilly, Incyte, Kyowa Hakko Kirin, LEO Pharma, Merck, Novartis, Pfizer, Regeneron, Sanofi, and Tioga and Vanda Pharmaceuticals. D.M.P. was a consultant for Abbott Laboratories, Amgen, Asana BioSciences, LLC, Atacama Therapeutics, Bickel Biotechnology, Biofrontera AG, Celgene Corporation, Dermira, Dermavant Sciences, DUSA Pharmaceuticals, Inc, Eli Lilly and Company, LEO Pharma, US, Merck and Co, Inc, Novartis Pharmaceuticals Corp, Novo Nordisk A\/S, Ortho Dermatologics, Peplin, Inc, Pfizer, Inc, Photocure ASA, Promius Pharma, LLC, Regeneron Pharmaceuticals, Inc, Sanofi, Stiefel (a GSK company), TDM SurgiTech, Inc, TheraVida, Inc, and Valeant Pharmaceuticals International. J.D., M.B., and S.F. received research funding for the current study from Research Triangle Institute Health Solutions. Z.W. is an employee and shareholder of Regeneron Pharmaceuticals, Inc. C.C.C. is an employee and may hold stock and\/or stock options in Sanofi.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study was conducted in accordance with the ethical principles of the Declaration of Helsinki of 1964 (including its later amendments) and the International Council for Harmonization Good Clinical Practice guideline. This study received Research Triangle Institute institutional review board approval.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}